Extended-duration dosing and distribution of dalbavancin into bone and articular tissue

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 1849-1855

  Dunne, Michael W ^a   Puttagunta, Sailaja ^a   Sprenger, Craig R ^c,d   Rubino, Chris ^b   Van Wart, Scott ^b   Baldassarre, James ^a  

^a Durata Therapeutics   (United States)

^b INSTITUTE FOR CLINICAL PHARMACODYNAMICS   (United States)

^c PRACS Institute Ltd   (United States)

^d Novum PRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DALBAVANCIN; ANTIINFECTIVE AGENT; TEICOPLANIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; ARTICULAR CARTILAGE; BONE TISSUE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG PENETRATION; DRUG TISSUE LEVEL; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN TISSUE; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; AGED; ANALOGS AND DERIVATIVES; BONE; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; NORMAL HUMAN; SKIN; SYNOVIAL FLUID; TISSUE DISTRIBUTION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BONE AND BONES; CARTILAGE, ARTICULAR; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; SKIN; SYNOVIAL FLUID; TEICOPLANIN; TISSUE DISTRIBUTION; YOUNG ADULT;

EID: 84928911214     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04550-14     Document Type: Article

References (19)

1. Yeo A, Ramachandran M. 2014. Acute haematogenous osteomyelitis in children. BMJ 348:g66. http://dx.doi.org/10.1136/bmj.g66.
2. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Ryback MJ, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 52:e18. http://dx.doi.org/10.1093/cid/ciq146.
3. Fraimow HS. 2009. Systemic antimicrobial therapy in osteomyelitis. Semin Plast Surg 23:90-99. http://dx.doi.org/10.1055/s-0029-1214161.
4. David MZ, Daum RS, Bayer AS, Chambers HF, Fowler VG, Miller LG, Ostrowsky B, Baesa A, Boyle-Vavra S, Eells SJ, Garcia-Houchins S, Gialanella P, Macias-Gil R, Rude TH, Ruffin F, Sieth JJ, Volinski J, Spellberg B. 2014. Staphylococcus aureus bacteremia at 5 US academic medical centers, 2008-2011: significant geographic variation in community-onset infections. Clin Infect Dis 59:798-807. http://dx.doi.org/10.1093/cid/ciu410.
5. Barnea Y, Carmeli Y, Kuzmenko B, Navon-Venezia S. 2008. Staphylococcus aureus mediastinitis and sternal osteomyelitis following median sternotomy in a rat model. J Antimicrob Chemother 62:1339-1343. http://dx.doi.org/10.1093/jac/dkn378.
6. Garazzino S, Aprato A, Baietto L, D'Avolio A, Maiello A, De Rosa FG, Aloj D, Siccardi M, Biasibetti A, Massè A, Di Perri G. 2008. Glycopeptide bone penetration in patients with septic pseudoarthrosis of the tibia. Clin Pharmacokinet 47:793-805. http://dx.doi.org/10.2165/0003088-200847120-00004.
7. Massias L, Dubois C, de Lentdecker P, Brodaty O, Fischler M, Farinotti R. 1992. Penetration of vancomycin in uninfected sternal bone. Antimicrob Agents Chemother 36:2539-2541. http://dx.doi.org/10.1128/AAC.36.11.2539.
8. Jones RN, Sader HS, Flamm RK. 2013. Update of dalbavancin spectrum and potency in the U S A: report from the SENTRY Antimicrobial Surveillance Program (2011). Diagn Microbiol Infect Dis 75:304-307. http://dx.doi.org/10.1016/j.diagmicrobio.2012.11.024.
9. Lazzarini L, Lipsky BA, Mader JT. 2005. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis 9:127-138. http://dx.doi.org/10.1016/j.ijid.2004.09.009.
10. Lopez S, Hackbarth C, Joaquim Trias RG, Jabes D, Goldstein BP. 2005. In vitro antistaphylococcal activity of dalbavancin, a novel glycopeptide. J Antimicrob Chemother 55(Suppl S2):ii21-ii24.
11. Goldstein BP, Draghi DC, Sheehan DJ, Hogan P, Sahm DF. 2007. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 51:1150-1154. http://dx.doi.org/10.1128/AAC.00620-06.
12. Feigin RD, Pickering LK, Anderson D, Keeney RE, Shackleford PF. 1975. Clindamycin treatment of osteomyelitis and septic arthritis in children. Paediatrics 55:213-223.
13. Solon EG, Dowell JA, Lee J, King SP, Damle BD. 2007. Distribution of radioactivity in bone and related structures following administration of [14C]dalbavancin to New Zealand White rabbits. Antimicrob Agents Chemother 51:3008-3010. http://dx.doi.org/10.1128/AAC.00020-07.
14. Wang Z, Deurenberg P, Wang W, Pietrobelli A, Baumgartner RN, Heymsfield SB. 1999. Hydration of fat-free body mass: new physiological modeling approach. Am J Physiol 276:E995-E1003.
15. Andes D, Craig WA. 2007. In vivo pharmacodynamic activity of the glycopeptide dalbavancin. Antimicrob Agents Chemother 51:1633-1642. http://dx.doi.org/10.1128/AAC.01264-06.
16. Dunne MW, Zhou M, Darpo B. 22 January 2015. A thorough QT study with dalbavancin: a novel lipoglycopeptide antibiotic for the treatment of acute bacterial skin and skin structure infections. Int J Antimicrobial Agents http://dx.doi.org/10.1016/j.ijantimicag.2014.12.021.
17. Baird P, Hughes S, Sullivan M, Willmot I. 1978. Penetration into bones and tissues of clindamycin phosphate. Postgrad Med J 54:65-67. http://dx.doi.org/10.1136/pgmj.54.628.65.
18. Nicholas P, Meyers BR, Levy RN, Hirschman SZ. 1975. Concentration of clindamycin in human bone. Antimicrob Agents Chemother 8:220-221. http://dx.doi.org/10.1128/AAC.8.2.220.
19. Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW. 2014. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 370:2169-2178. http://dx.doi.org/10.1056/NEJMoa1310480.